Primary Handling Editors: Keith Syson Chan, Christina Karlsson Rosenthal and Mengtan Xing
Standard maintenance: - Type I-II: 0.5 mg twice per week - Type III-IV: 0.5 mg once per week - Type V-VI: 0.5 mg every 2-3 weeks Alternative approach: Some users prefer a single larger weekly dose (1.0 mg once per week instead of 0.5 mg twice per week)
This could change over the next few weeks, as the rollout of these new treatments begins across the country
Some of the critical aspects of these legal cases involve: Drug manufacturers being accused of negligence Plaintiffs seeking compensation for health complications Potential formation of multidistrict litigation (MDL) to streamline numerous cases Should the number of lawsuits grow substantially, the judicial panel may consolidate these cases in a federal court to manage the litigation more efficiently
Then in May 2025, the first direct head-to-head trial SURMOUNT-5 was published in the New England Journal of Medicine , putting the two medications head-to-head in the same patients, at the same time, under the same conditions
Heres how its different from previous meds: Retatrutide is a triple agonist, meaning it targets three different hormone receptors, rather than one (like Ozempic) or two (like Mounjaro or Zepbound)